Research Article
177Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer
Table 4
PSA levels in patients before and after treatment.
| | Patient no. (no. of cycles, total activity administered (GBq)) | PSA levels (ng/mL) (SUVmax in soft tissue tumor lesions) | | Before treatment | After treatment |
| | 1 (4, 18.5) | 58 (73) | 4 (1) | | 2 (2, 7.4) | 53 (32) | 55 (14) | | 3 (2, 7.4) | 20 (33) | 30 (17) | | 4 (1, 5.5) | 31 (46) | 18 (4) | | 5 (1, 7.4) | 101 (38) | 45 (16) | | 6 (2, 7.4) | 46 (33) | 25 (19) | | 7 (2, 7.4) | 217 (56) | 322 (21) | | 8 (2, 7.4) | 34 (47) | 11 (26) | | 9 (1, 7.4) | 37 (101) | 40 (33) | | 10 (1, 3.7) | 182 (79) | 76 (28) |
|
|
Progressive disease: bone metastases. |
